High-performance liquid chromatography analysis of curcumin in rat plasma: Application to pharmacokinetics of polymeric micellar formulation of curcumin

Biomedical Chromatography

Volumn 21, Issue 5, 2007, Pages 546-552

  Ma, Zhengshuan ^a   Shayeganpour, Anooshirvan ^a   Brocks, Dion R ^a   Lavasanifar, Afsaneh ^a   Samuel, John ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Curcumin; HPLC; Pharmacokinetics; Polymeric micelle

Indexed keywords

BODY FLUIDS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MICELLES; PHARMACOKINETICS; RATS;

CURCUMIN; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHODS; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; INTERNAL STANDARDS; MICELLARS; PERFORMANCE; POLYMERIC MICELLE; RAT PLASMA; SIMPLE++;

ACETONITRILE;

ACETONITRILE; BUFFER; COPOLYMER; CURCUMIN; MACROGOL; POLYMER;

ACCURACY; ANALYTICAL ERROR; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICELLAR LIQUID CHROMATOGRAPHY; NONHUMAN; RAT; RELIABILITY; ULTRAVIOLET RADIATION;

RATTUS;

EID: 34248403310     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.795     Document Type: Article

References (24)

1. Aliabadi HM, Brocks DR and Lavasanifar A. Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution. Biomaterials 2005a; 26: 7251.
2. Aliabadi HM, Mahmud A, Sharifabadi AD and Lavasanifar A. Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. Journal of Controlled Release 2005b; 104: 301.
3. Atsumi T, Murakami Y, Shibuya K, Tonosaki K and Fujisawa S. Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression, by curcumin and its analog, alpha-diisoeugenol. Anticancer Research 2005; 25: 4029.
4. Belakavadi M and Salimath BP. Mechanism of inhibition of ascites tumor growth in mice by curcumin is mediated by NF-κB and caspase activated DNase. Molecular and Cellular Biochemistry 2005; 273: 57.
5. Brocks DR and Betageri GV. Enhanced oral absorption of halofantrine enantiomers after encapsulation in a proliposomal formulation. Journal of Pharmacy and Pharmacology 2002; 54: 1049.
6. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC and Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Research 2001; 21: 2895.
7. Davies B and Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 1993; 10: 1093.
8. Gelderblom H, Verweij J, Nooter K and Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer 2001; 37: 1590.
9. Gururaj AE, Belakavadi M, Venkatesh DA, Marme D and Salimath BP. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochemical and Biophysical Research Communications 2002; 297: 934.
10. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K and Kakizoe T. NK105, a pacitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. British Journal of Cancer 2005; 92: 1240.
11. Hoehle SI, Pfeiffer E, Solyom AM and Metzler M. Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver. Journal of Agricultural and Food Chemistry 2006; 54: 756.
12. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP and Gescher A. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Research 2001; 61: 1058.
13. Kommareddy S, Tiwari SB and Amiji MM. Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technology in Cancer Research and Treatment 2005; 4: 615.
14. Liu A, Lou H, Zhao L and Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. Journal of Pharmaceutical and Biomedical Analysis 2006; 40: 720.
15. Molavi O, Shayeganpour A, Somayaji V, Hamdy S, Brocks DR, Lavasanifar A, Kwon OS and Samuel J. Development of a sensitive and specific liquid chromatography/mass spectrometry method for the quantification of cucurbitacin I (JSI-124) in rat plasma. Journal of Pharmacy and Pharmaceutical Sciences 2006; 9: 158.
16. Pak Y, Patek R and Mayersohn M. Sensitive and rapid isocratic liquid chromatography method for the quantitation of curcumin in plasma. Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences 2003; 796: 339.
17. Sharma RA, Gescher AJ and Steward WP. Curcumin: the story so far. European Journal of Cancer 2005; 41: 1955.
18. Shishodia S, Amin HM, Lai R and Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochemical Pharmacology 2005; 70: 700.
19. Shishodia S, Sethi G and Aggarwal BB. Curcumin: getting back to the roots. Annals of the New York Academy of Sciences 2005; 1056: 206.
20. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R and Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica 1998; 64: 353.
21. Shuai X, Ai H, Nasongkla N, Kim S and Gao J. Micellar carriers based on block copolymers of poly(epsion-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. Journal of Controlled Release 2004; 98: 415.
22. Singh S and Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anti-cancer Agents in Medicinal Chemistry 2006; 6: 259.
23. Tonnesen HH, Masson M and Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. International Journal of Pharmaceutics 2002; 244: 127.
24. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY and Lin JK. Stability of curcumin in buffer solutions and characterization of its degradation products. Journal of Pharmaceutical and Biomedical Analysis 1997; 15: 1867.